Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
02 août 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new...
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
29 juil. 2022 09h15 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
09 juin 2022 07h33 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
18 mai 2022 16h10 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
12 mai 2022 16h05 HE
|
Salarius Pharmaceuticals, Inc.
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein...
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
11 mai 2022 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
05 mai 2022 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
22 avr. 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
10 mars 2022 16h05 HE
|
Salarius Pharmaceuticals, Inc.
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing...
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
03 mars 2022 07h31 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...